Davita Inc vs Micron Technology, Inc. — how do they compare? Davita Inc trades at $175.04 (market cap $11.29B), while Micron Technology, Inc. trades at $1,051.83 (market cap $1.17T). The key difference: Micron Technology, Inc. is far larger — about 103.6× Davita Inc's market cap, and Micron Technology, Inc. pays a 0.06% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Micron Technology, Inc. for 48 Days on average.
| DVA | MU | |
|---|---|---|
Market Cap | $11.29B | $1.17T |
Volume | 582,204 | 29,425,906 |
Sector | Health | Technology |
52-Week High | $240.96 | $1.21K |
52-Week Low | $103.87 | $181.60 |
Typical Hold Time | 113 Days | 48 Days |
Enterprise Value | $24.01B | $1.13T |
Dividend Yield | — | 0.06% |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, showing technical bearish signals with price near key support at $175. Fundamentally, the company demonstrates solid earnings performance with three consecutive quarterly beats and attractive valuation metrics including a P/E of 14.98 and P/S of 0.88. Recent expansion of value-based care partnerships with Humana positions the company for continued growth in kidney care services.
The stock presents a compelling value opportunity with analyst consensus target of $235.67 offering 33% upside potential, though investors face risks from regulatory pressures and narrowing profit margins. Warren Buffett's significant ownership (45%) and institutional buying activity provide confidence, but the bearish technical outlook and mixed analyst ratings (43% Buy, 52% Hold) suggest cautious optimism is warranted.
Micron Technology (MU) trades at $1,088, up 4.06% today, reflecting strong momentum amid a bullish technical outlook. The stock shows robust fundamentals with a P/E of 14.64, net income margin of 63.8%, and three consecutive quarterly earnings beats. Recent news highlights multi-year growth driven by AI memory demand and strategic customer agreements covering 35% of revenue through 2030.
Outlook remains positive with analyst consensus favoring Buy ratings (82.85%) and a $1,590 price target. Key risks include cyclical memory pricing and slowing growth projections, but institutional sentiment and cash flow trends support upside potential for investors seeking AI-driven semiconductor exposure.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →